FDA Warning Letter due to Faulty Sampling
Register now for ECA's GMP Newsletter
This FDA Warning Letter issued to a Chinese manufacturer of medicinal products on 07 February, 2018 is based on an inspection which took place in April 2017.
It was discovered during the inspection that the company did not fully test the active pharmaceutical ingredients and excipients used in the production of their OTC products. It was also criticised that identity testing had only been performed on active substances and not on the excipients used. All batches of starting materials must be tested for identity before the release by the quality control unit.
The company's response from 07 May, 2017, was deemed inadequate by the FDA.
Amongst the points the FDA additionally requested were a detailed sampling plan and testing plan for all incoming starting materials.
Please also see the complete FDA Warning Letter to Shanghai Weierya Daily Chemicals.
Related GMP News
13/03/2024
GMP Conferences by Topics
- General Quality Assurance and GMP Compliance Topics
- Hygiene
- General Microbiology Topics
- Regulatory Affairs
- Development
- General Analytics Topics
- Good Distribution Practice
- Sterile Manufacturing
- Computer Validation
- General Qualification/Validation Topics
- General Engineering Topics
- APIs/Excipients
- GMP Basic Training Courses
- Medical Devices and Combination Products
- Packaging and Packaging Material
- Data Integrity
- Qualified Person (QP)
- GMP Auditing
- Documentation
- Cleaning Validation
- General IT Compliance Topics
- Impurities
- OOS / OOE / OOT
- Material Testing
- Validation of Analytical Methods
- Analytical Instrument Qualification
- Stability Testing
- Microbiological Testing
- Technology
- General Manufacturing Topics
- Solid Dosage Forms/Semi-Solid Dosage Forms
- Biotechnology/Blood/ATMP
- Herbal Drug Products/Cannabis/Radiopharmaceuticals
- Others